PRDM14

Across TCGA pan-cancer cohorts, PRDM14 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated PRDM14 data layer compared with 6 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PRDM14 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PRDM14 expression acts as an unfavorable survival marker, although some lineages such as GBM and BRCA show a favorable association.

OV, LIHC, and CHOL are the cancer types where PRDM14 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Tertile	III,IV	0.775	0.861	.007	54	view →
LIHC	OS	Tertile	All	0.553	0.734	<.001	49	view →
CHOL	OS	Tertile	III,IV	0.024	0.772	.008	36	view →
SCLC	DFS	Quartile	All	0.234	0.780	<.001	33	view →
ACC	DFS	Tertile	All	0.219	0.658	.036	18	view →
SARC	DFS	Quartile	All	0.211	0.440	.010	18	view →
MESO	DFS	Tertile	III,IV	0.222	0.430	.038	18	view →
READ	OS	Tertile	IV	0.514	0.786	.036	18	view →
UVM	DFS	Tertile	III,IV	0.138	0.745	.002	15	view →
LUSC	DFS	Tertile	III,IV	0.211	0.680	.040	12	view →
KIRC	DFS	Tertile	IV	0.242	0.551	.032	6	view →
GBM	OS	Median	All	0.223	0.158	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

PRDM14–OV (OS)

Open the OV breakdown →